SCHEMBL10025571

SCHEMBL10025571

CCOC(=O)c1cnc2cnccn12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.45
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 5/20 0.44
GAA P10253 4/20 0.44
GLA P06280 2/20 0.44
HSD17B10 Q99714 4/20 0.41
CASP1 P29466 2/20 0.41
CASP7 P55210 2/20 0.41
ALOX15 P16050 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
RECQL P46063 1/20 0.40
IDO1 P14902 2/20 0.40
JMJD6 Q6NYC1 1/20 0.39
TBXAS1 P24557 1/20 0.39
CDC7 O00311 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24054547 0.82 KDM4E (0.36) TGFBR1KDM4EALDH1A1HPGDGAA
SCHEMBL18589535 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL20226852 0.80 DDR1 (0.36) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL11063491 0.79 MAPK1 (0.58) TGFBR1KDM4EALDH1A1HPGDGAA
SCHEMBL14957015 0.78 KDM4E (0.47) TGFBR1KDM4EALDH1A1HPGDGAA
SCHEMBL14742881 0.78 KDM4E (0.70) TGFBR1KDM4EALDH1A1HPGDGAA
SCHEMBL1203406 0.78 NPC1 (0.35) KDM4EPIK3CACYP1A2CYP3A4CYP2C9
SCHEMBL9941870 0.77 KDM4E (0.54) TGFBR1KDM4EALDH1A1HPGDGAA
SCHEMBL30980408 0.77 ALDH1A1 (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL2051512 0.76 GAA (0.53) TGFBR1KDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615454-A1 SOS1 INHIBITORS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-09-17 EP disclosed
US-20240190868-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) 2024-06-13 US disclosed
WO-2024102952-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-16 WO disclosed
WO-2024102952-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-16 WO disclosed
EP-2995611-B1 ALPHA-SUBSTITUTED GLYCINEAMIDE DERIVATIVE KISSEI PHARMACEUTICAL (JP) 2017-10-11 EP disclosed
US-9566277-B2 Methods of using phthalazinone ketone derivatives JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2017-02-14 US disclosed
US-9566277-B2 Methods of using phthalazinone ketone derivatives JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2017-02-14 US disclosed
US-9566277-B2 Methods of using phthalazinone ketone derivatives JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2017-02-14 US disclosed
US-9458092-B2 α-Substituted glycinamide derivative KISSEI PHARMACEUTICAL CO., LTD. (JP) 2016-10-04 US disclosed
US-20160151367-A1 METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2016-06-02 US disclosed
US-9273052-B2 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-03-01 US disclosed
US-9273052-B2 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-03-01 US disclosed
US-9273052-B2 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2016-03-01 US disclosed
WO-2015004481-A1 IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) ASTEX THERAPEUTICS LIMITED (GB) 2015-01-15 WO disclosed
WO-2015004481-A1 IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) ASTEX THERAPEUTICS LIMITED (GB) 2015-01-15 WO disclosed
EP-2604610-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) 2013-06-19 EP disclosed
US-20130131068-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2013-05-23 US disclosed
US-20130131068-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2013-05-23 US disclosed
US-20130131068-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2013-05-23 US disclosed
WO-2012019427-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF 上海恒瑞医药有限公司 (CN) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190868-A1 SOS1 INHIBITORS SOS1, SOS2, SOST TGFBR1 648/4885KDM4E 4441/4885ALDH1A1 3287/4885
US-20160151367-A1 METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES PARP1, PARP2, PARP3 TGFBR1 2940/4885KDM4E 578/4885ALDH1A1 391/4885
US-20130131068-A1 PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF PARP1, PARP2, PARP4 TGFBR1 2939/4885KDM4E 374/4885ALDH1A1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.